[1] |
Taylor PN,Zhang L,Lee RWJ,et al.New insights into the pathogenesis and nonsurgical management of Graves orbitopathy[J].Nat Rev Endocrinol,2020,16(2):104-116.
|
[2] |
Liu Z,Ke SR,Shi ZX,et al.Dynamic transition of Tregs to cytotoxic phenotype amid systemic inflammation in Graves’ophthalmopathy[J].JCI Insight,2024,9(22):e181488.
|
[3] |
Buonfiglio F,Ponto KA,Pfeiffer N,et al.Redoxmechanisms in autoimmune thyroid eye disease[J].Autoimmun Rev,2024,23(5):103534.
|
[4] |
Ma Q,Hai Y,Duan Y,etal.Inflammatory profiling and immune cell infiltration in dysthyroid optic neuropathy:insights from bulk RNA sequencing[J].Front Immunol,2025,16:185.
|
[5] |
Fernando R,Atkins S,RaychaudhuriN,etal.Human fibrocytes coexpress thyroglobulin and thyrotropin receptor[J].Proc Natl Acad Sci,2012,109(19):7427-7432.
|
[6] |
Kim JY,Park S,Lee HJ,et al.Functionally enhanced placentaderived mesenchymal stem cells inhibit adipogenesis in orbital fibroblasts with Graves’ophthalmopathy[J].Stem Cell Res Ther,2020,11(1):726.
|
[7] |
Li Z,Wang M,Tan J,etal.Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy[J].Cell Rep Med,2022,3(8):100699.
|
[8] |
Bahn RS.Graves′Ophthalmopathy[J].N Engl JMed,2010,362(8):726-738.
|
[9] |
Lanzolla G,Marinò M,Menconi F.Graves disease:latest understanding of pathogenesis and treatment options[J].Nat Rev Endocrinol,2024,20(11):647-660.
|
[10] |
Shu X,Shao Y,Chen Y,et al.Immune checkpoints:new insights into the pathogenesis of thyroid eye disease[J].Front Immunol,2024,PMID:38817600.
|
[11] |
Bartalena L,Tanda ML.Current concepts regarding Graves′orbitopathy[J].J Intern Med,2022,292(5):692-716.
|
[12] |
Al-BadriWKW,Jellema HM,Potvin ARGG,etal.Psychological aspects of Graves′ophthalmopathy[J].Endocr Connect,2024,13(9):e240259.
|
[13] |
Chen YY,Wei YH,Liao SL.Postoperative residual vertical deviation affects quality of life in Asian patients with thyroidassociated ophthalmopathy(Graves ophthalmopathy)[J].Jpn J Ophthalmol,2023,67(3):326-334.
|
[14] |
Chen M,Tang S,Yan J.Assessment of surgical strategies for management of complicated strabismus reoperation in Graves’ophthalmopathy[J].Int Ophthalmol,2024,44(1):19.
|
[15] |
Eckstein A,Schittkowski M,Esser J.Surgical treatment of Graves′ophthalmopathy[J].Best Pract Res Clin Endocrinol Metab,2012,26(3):339-358.
|
[16] |
Suo NC,Lei CL,Zhang YC,et al.Effects of latanoprost on the expression of TGF-β1 and Wnt/β-catenin signaling pathway in the choroid of form-deprivation myopia rats[J].Cell Mol Biol,2020,66(6):71-75.
|
[17] |
Boulakh L,Nygaard B,Bek T,et al.Nationwide incidence of thyroid eye disease and cumulative incidence of strabismus and surgical interventions in Denmark[J].JAMA Ophthalmol,2022,140(7):667.
|
[18] |
Marino M,Rotondo DG,Menconi F,et al.Role of genetics and epigenetics in Graves′orbitopathy[J].Eur Thyroid J,2024,13(6):e240179.
|
[19] |
Wang Y,Gao S,Cao F,et al.Ocular immune-related diseases:molecular mechanisms and therapy[J].Med Comm,2024,5(12):207.
|
[20] |
Kim DW,Kim S,Han J,et al.Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway[J].JCI Insight,2024,PMID:39704170.
|
[21] |
Chang HH,Wu SB,Tsai CC.A review of pathophysiology and therapeutic strategies targeting TGF-βin Graves′ophthalmopathy[J].Cells,2024,13(17):1493.
|
[22] |
Akbari MR,Ameri A,Keshtkar Jaafari AR,et al.Botulinum toxin injection for restrictive myopathy of thyroid-associated orbitopathy:success rate and predictive factors[J].J AAPOS,2016,20(2):126-130.
|
[23] |
崔好好,邵庆.A型肉毒素在甲状腺相关眼病治疗中的应用[J].国际眼科杂志,2023,23(7):1120-1125.
|
[24] |
AkbariMR,Mirmohammadsadeghi A,Mahmoudzadeh R,et al.Management of thyroid eye disease-related strabismus[J].JCurr Ophthalmol,2020,32(1):1-13.
|
[25] |
Wei L,Huang Q,Tu Y,et al.Plasma exosomes from patients with active thyroid-associated orbitopathy induce inflammation and fibrosis in orbital fibroblasts[J].J Transl Med,2024,22(1):994.
|
[26] |
吴元.甲状腺相关斜视的治疗策略[J].中国斜视与小儿眼科杂志,2021,29(1):42-45.
|
[27] |
许丽敏,荣军博,郎丽娟,等.甲状腺相关眼病所致限制性斜视的手术效果[J].中华眼外伤职业病杂志,2021,43(5):328-333.
|
[28] |
Lu TJ,Amarikwa L,Sears CM,et al.Advances in the treatment of thyroid eye disease associated extraocularmusclemyopathy and optic neuropathy[J].Curr Neurol Neurosci Rep,2022,22(6):313-325.
|
[29] |
Dal-Canto AJ,Crowe S,Perry JD,et al.Intraoperative relaxed muscle positioning technique for strabismus repair in thyroid eye disease[J].Ophthalmology,2006,113(12):2324-2330.
|
[30] |
Nguyen VT,Park DJJ,Levin L,et al.Correction of restricted extraocularmuscle motility in surgical management of strabismus in Graves′ophthalmopathy[J].Ophthalmology,2002,109(2):384-388.
|
[31] |
Liao SL,Wei YH,Chuang AC.The role of rectus muscle myectomy in themanagementof large-angle strabismus for Graves′ophthalmopathy[J].Eye(Lond),2017,31(7):1027-1033.
|
[32] |
马惠芝,李宁冬,赵堪兴,等.直肌悬吊术在治疗甲状腺相关性眼病手术中的应用[J].中国实用眼科杂志,2007,25(7):796-798.
|
[33] |
郑磊,阙传红.甲状腺相关性眼病所致限制性斜视手术效果观察[J].中华眼外伤职业病杂志,2015,37(6):447-449.
|
[34] |
Tian H,Wang Y,Li J,et al.Prognostic value of extraocular muscles for intraocular pressure in thyroid-associated ophthalmopathy patients[J].Quant Imaging Med Surg,2023,13(9):5727-5736.
|
[35] |
Li X,Bai X,Liu Z,et al.The effect of inferior rectusmuscle thickening on intraocular pressure in thyroid-associated ophthalmopathy[J].JOphthalmol,2021,PMID:33564471.
|